T-Alpha Therapeutics

T-Alpha Therapeutics is a South San Francisco-based biotechnology company focused on developing next-generation T-cell receptor (TCR) engineered T-cell therapies for solid tumors. Founded by industry veterans with extensive experience in cell therapy, the company utilizes a proprietary platform to discover and optimize TCRs against novel and validated intracellular targets. T-Alpha's approach aims to improve the potency, persistence, and safety of TCR-T therapies, specifically addressing the challenges of the immunosuppressive solid tumor microenvironment. The company is currently in the preclinical stage, advancing a pipeline of candidates designed to provide precise and durable responses for cancer patients. By leveraging advanced immunology and engineering, T-Alpha seeks to expand the reach of cellular immunotherapy beyond hematological malignancies.